Please login to the form below

Not currently logged in
Email:
Password:

Joachim Hasenmaier joins Boehringer’s board in senior shake-up

Company also appoints new board division of biopharmaceuticals and operations to reflect increased focus on biosimilars

Joachim Hasenmaier - BoehringerBoehringer Ingelheim has appointed Dr Joachim Hasenmaier (pictured) to its board of managing directors to head both consumer and animal health in a series of changes at the top for the German pharma company.

Dr Hasenmaier, who assumes his new role from October 1, 2012, has been with Boehringer since 2001, serving initially as divisional head, animal health, before taking over as regional business manager for Northern Europe and Canada in 2011.

“Joachim Hasenmaier's appointment is the outcome of a long term human resource strategy,” said Christian Boehringer, chair of the company's shareholders' committee.

“Recognising the special focus of animal health and the consumer healthcare business on the end-customer, it is meaningful to combine responsibilities in one board division.”

In addition, Professor Wolfram Carius, previously responsible for the board division of human resources and operations, will take charge of the new board division of biopharmaceuticals and operations to reflect Boehringer's increased focus on biosimilars.

Board chair Professor Andreas Barner will take over responsibilities for human resources as well as remaining board member for research & development and medicine.

The finance board division has also now been “distinctly separated” from the rest of the board divisions, with responsibility to remain with Hubertus von Baumbach.

Engelbert Tjeenk-Willink also stays in charge of Boehringer's prescriptions medicine business.

10th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...